Charles Engbers
- Biomaterials top 2%
- Nanoparticle-Based Drug Delivery 6
- Surfaces, Coatings and Films top 10%
- Pharmaceutical Science top 10%
-
- RNA Interference and Gene Delivery 2
- Cancer therapeutics and mechanisms 1
-
- Growth Hormone and Insulin-like Growth Factors 3
-
- Cancer Treatment and Pharmacology 3
-
- Digestive system and related health 2
-
- Nanoplatforms for cancer theranostics 2
-
- Infant Nutrition and Health 1
- Co-authors
- Samuel ZalipskyMartin C. WoodleMary S. NewmanMichael AmanteaGail ColbernPeter K. WorkingNeil I. GoldsteinJennifer Harding
- Journals
- Bioconjugate Chemistry (3 papers)Cancer Chemotherapy and Pharmacology (2 papers)Endocrinology (2 papers)
- Partner nations
- United StatesUnited KingdomArgentina
In The Last Decade
Charles Engbers
12 papers receiving 875 citations
Peers
Comparison fields: 5 of 87
- Biomaterials 521
- Surfaces, Coatings and Films 72
- Pharmaceutical Science 52
- Molecular Biology 471
- Polymers and Plastics 90
Countries citing papers authored by Charles Engbers
This map shows the geographic impact of Charles Engbers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Engbers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Engbers more than expected).
Fields of papers citing papers by Charles Engbers
This network shows the impact of papers produced by Charles Engbers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Engbers. The network helps show where Charles Engbers may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Charles Engbers, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2007 | 35 | |
| 2 | 2007 | 70 | |
| 3 | Plasma, tissue and tumor disposition of STEALTH® liposomal CKD-602 (S-CKD602) and non-liposomal CKD-602, a camptothecin analogue, in mice bearing A375 human melanoma xenografts | 2006 | 3 |
| 4 | Allometric scaling of STEALTH® liposomal anticancer agents | 2005 | 4 |
| 5 | 1999 | 239 | |
| 6 | 1997 | 154 | |
| 7 | 1996 | 18 | |
| 8 | 1995 | 47 | |
| 9 | 1995 | 2 | |
| 10 | 1994 | 283 | |
| 11 | 1992 | 35 | |
| 12 | 1992 | 22 |
About Charles Engbers
Charles Engbers is a scholar working on Biomaterials, Process Chemistry and Technology and Endocrinology, Diabetes and Metabolism, having authored 12 papers that have together received 912 indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (6 papers), Growth Hormone and Insulin-like Growth Factors (3 papers), Cancer Treatment and Pharmacology (3 papers), RNA Interference and Gene Delivery (2 papers), Digestive system and related health (2 papers), Nanoplatforms for cancer theranostics (2 papers), Cancer therapeutics and mechanisms (1 paper) and Infant Nutrition and Health (1 paper). The work is most often cited by research in Biomaterials (521 citations), Surfaces, Coatings and Films (72 citations) and Pharmaceutical Science (52 citations). Charles Engbers has collaborated with scholars based in United States, United Kingdom and Argentina. Frequent co-authors include Samuel Zalipsky, Martin C. Woodle, Mary S. Newman, Michael Amantea, Gail Colbern, Peter K. Working, Neil I. Goldstein, Jennifer Harding, Frank Talamantes and Ross Barnard. Their work appears in journals such as Bioconjugate Chemistry, Cancer Chemotherapy and Pharmacology, Endocrinology, Cancer Research and American Journal of Physiology-Endocrinology and Metabolism.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.